No abstract

Background: Retinopathy of Prematurity (ROP) is one of the most common causes of preventable blindness in children. Recent advances in the neonatology have increased preterm survival and so has the ROP incidence. Studies all over the world and across the country have shown a wide range for incidence of ROP and so it is difficult to gauge the exact incidence, especially in our region.Methods: This prospective observational study was conducted in neonatal units of the Department of Paediatrics, Dr. S. N. Medical College, Jodhpur for a duration of six months. All newborns delivered in hospitals associated with Dr S. N. Medical College with gestation age at birth <34weeks and 34-36weeks associated with risk factors subjected to ROP screening by indirect ophthalmoscope by a trained ophthalmologist. Neonates with congenital cataract, hazy cornea, abnormal anterior chamber and those who expired or lost to follow up before sufficient examination could be done were excluded.Results: Out of 250 newborns screened, 34 (13.6%) were found positive for ROP and out of these 34, 18 (52.94%) had stage I, 11 (32.35%) had stage II, 5 (14.7%) had stage III and none for stage IV and V. Prolonged oxygen therapy, low birth weight, apnoea and sepsis were found to be significant risk factor (p<0.05) with the relative risk of 12.49, 3.71, 3.03 and 1.91 respectively.Conclusions: ROP is a preventable cause of blindness in children. Thus, its screening is indispensable and it has to be intensified in presence of risk factors such as prolonged oxygen therapy, low birth weight, apnoea and sepsis.

Purpose Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) is a current standard of care for locoregionally advanced gastric adenocarcinomas. There is limited real world data with regard to the tolerance and efficacy of this regimen. Materials and Methods This is a retrospective analysis of gastric cancer patients who were offered neoadjuvant perioperative modified FLOT regimen between December 2016 and October 2018, at the Tata Memorial Hospital, Mumbai. Chemotherapy-related side-effects are reported along with overall survival (OS), as calculated by Kaplan-Meier method. Results Three hundred and forty-three consecutive patients were started on neoadjuvant chemotherapy (NACT) with mFLOT of which 298 patients (87%) completed the planned treatment. A total of 294 patients (86%) underwent curative resection of gastric cancer. Common grade 3 and grade 4 toxicities during NACT were diarrhea in 42 patients (12%) and febrile neutropenia in 27 patients (8%). Toxic death was seen in nine (2.6%) patients. A total of 264 patients (77%) completed planned adjuvant chemotherapy. Common grade 3 and grade 4 toxicities during adjuvant therapy were diarrhea in 42 patients (12%) and febrile neutropenia in 16 patients (6%). With a median follow-up of 19 months, the estimated 2-year median OS was 69.4%. Conclusion Administration of modified FLOT regimen in locoregionally advanced gastric cancers is feasible in clinical practice with high completion rates, though requiring dose modifications due to the incidence of clinically relevant grade 3 to 5 toxicities. Early outcomes with the regimen are on par with survivals from the FLOT-AIO study.

No abstract